In his 1st century opus on medicine, Celsus described treatments for diminishing the scars of soldiers. 1 Th ese regimens have changed little over the subsequent millennia. Surgical scar excision and primary or local fl ap closure remain the standards for treating hypertrophic scarring. However, scars in proximity to characterizing facial features may pose challenges to obtaining a favorable outcome. Hypertrophic and keloid scars are particularly diffi cult to treat, and they can recur.
As cosmetic surgery evolves, patients have become accustomed to the benefi ts of less invasive approaches. As a result, newer products such as light-based devices, fi llers, and neuromodulators have been incorporated into treatment regimens. Th e results of combinations of 5-fl uorouracil (5-FU), triamcinolone, and laser treatments have been promising. 2, 3 Over the past 4 years, the senior author (S.H.D.) has been using a combination of 5-FU, triamcinolone, and a botulinum neuromodulator for the treatment of hypertrophic and keloid scarring. Th e success of this technique is illustrated in the case of a 33-year-old man who presented 12 months aft er a vehicular accident in which he sustained trauma to the forehead. His lacerations had been sutured in an emergency department; there was no report of any foreign body embedded or diffi culty with the repair. Over the ensuing 6 months, hypertrophic scarring occurred.
Upon examination in the senior author's practice, the patient exhibited two large, vertically oriented hypertrophic scars (fi gure, A). Th e medial scar was located over the middle of the left eyebrow, and it measured approximately 4 × 1 cm. Th e lateral scar was located approximately 2 cm away, and it measured 3 × 1 cm. Th e closeness of the two scars prompted a decision to perform a staged excision. However, because the patient wanted both scars treated, we recommended medical injections for the lateral lesion.
Th e medial scar was surgically excised via a W-plasty excision. Six weeks postoperatively, the incision line was treated with diamond-bur dermabrasion. Th e lateral scar was treated with a series of monthly intralesional injections of 0.2 to 0.4 ml of a mixture containing 30 mg of 5-FU (50 mg/ml), 2 mg of triamcinolone (10 mg/ml), and 3 U of onabotulinumtoxinA (30 U/ ml); the mixture was delivered via a 1-ml tuberculin syringe. Nine months later, the results of the two scar treatments were similar, suggesting that a nonsurgical treatment can be as effi cacious as surgery in this regard. At 22 months post-treatment, the patient exhibited no signs of recurrence (fi gure, B). Based on the results of this case and others, our primary treatment for hypertrophic and keloid scars became the injection regimen, and surgery was relegated to status as a second-line, and oft en unnecessary, option.
Triamcinolone works by inhibiting glycosaminoglycan synthesis, fi broblast proliferation, and maturation. 4 Furthermore, triamcinolone exerts anti-infl ammatory eff ects by altering vascular permeability, thereby effectively inhibiting the delivery of oxygen, nutrients, and proinfl ammatory cytokines. 5 However, it has been our experience that scars treated with triamcinolone alone oft en recur. Th e addition of 5-FU, which is an antineoplastic agent, has been known to prevent scar recurrence 6 because it targets rapidly proliferating fibroblasts in the "S phase, " which are responsible for excessive collagen production. 7 Botulinum neuromodulators aid this process by paralyzing the areas near the scar and eliminating the repetitive tensile forces on the scar, leading to a reduction in fi broblast proliferation. 8 Specifi cally, the senior author has used onabotulinum-toxinA ever since effi cacy with hypertrophic scarring was previously demonstrated. 9 When combined, 5-FU, triamcinolone, and onabot-ulinumtoxinA target diff erent pathologies of scar development to produce superior results. Our regimen includes a series of monthly injections of 0.2 to 0.6 ml of a mixture of 30 mg of 5-FU, 2 mg of triamcinolone, and 3 U of onabotulinumtoxinA. Injections are administered intralesionally every 4 weeks until the appearance of the scar is aesthetically acceptable.
Although this particular report is anecdotal, we have used this combination on 48 patients over the past 4 years and, to date, no recurrences have been observed. 
